NO163618C - Analogifremgangsmaate for fremstilling av terapeutisk aktive aryloksy- og aryltio-hydroksypropyl-piperazin-acetanilider. - Google Patents

Analogifremgangsmaate for fremstilling av terapeutisk aktive aryloksy- og aryltio-hydroksypropyl-piperazin-acetanilider.

Info

Publication number
NO163618C
NO163618C NO841968A NO841968A NO163618C NO 163618 C NO163618 C NO 163618C NO 841968 A NO841968 A NO 841968A NO 841968 A NO841968 A NO 841968A NO 163618 C NO163618 C NO 163618C
Authority
NO
Norway
Prior art keywords
lower alkyl
independently hydrogen
together form
aryltio
acetanilides
Prior art date
Application number
NO841968A
Other languages
English (en)
Norwegian (no)
Other versions
NO841968L (no
NO163618B (no
Inventor
Arthur Frederick Kluge
Robin Douglas Clark
Arthur Martin Strosberg
Jean Claude Pascal
Roger Lewis Whiting
Original Assignee
Syntex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntex Inc filed Critical Syntex Inc
Publication of NO841968L publication Critical patent/NO841968L/no
Publication of NO163618B publication Critical patent/NO163618B/no
Publication of NO163618C publication Critical patent/NO163618C/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/15Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D303/00Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02Compounds containing oxirane rings
    • C07D303/12Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/18Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
    • C07D303/20Ethers with hydroxy compounds containing no oxirane rings
    • C07D303/22Ethers with hydroxy compounds containing no oxirane rings with monohydroxy compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/66Nitrogen atoms not forming part of a nitro radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
  • Cosmetics (AREA)
  • Pyridine Compounds (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
NO841968A 1983-05-18 1984-05-16 Analogifremgangsmaate for fremstilling av terapeutisk aktive aryloksy- og aryltio-hydroksypropyl-piperazin-acetanilider. NO163618C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/495,904 US4567264A (en) 1983-05-18 1983-05-18 Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry

Publications (3)

Publication Number Publication Date
NO841968L NO841968L (no) 1984-11-19
NO163618B NO163618B (no) 1990-03-19
NO163618C true NO163618C (no) 1990-06-27

Family

ID=23970461

Family Applications (1)

Application Number Title Priority Date Filing Date
NO841968A NO163618C (no) 1983-05-18 1984-05-16 Analogifremgangsmaate for fremstilling av terapeutisk aktive aryloksy- og aryltio-hydroksypropyl-piperazin-acetanilider.

Country Status (26)

Country Link
US (1) US4567264A (fr)
EP (1) EP0126449B1 (fr)
JP (1) JPS59219271A (fr)
KR (1) KR890000020B1 (fr)
AT (1) ATE31533T1 (fr)
AU (1) AU566489B2 (fr)
BR (1) BR1100474A (fr)
CA (1) CA1256874A (fr)
CS (1) CS246080B2 (fr)
DE (1) DE3468215D1 (fr)
DK (1) DK168535B1 (fr)
ES (1) ES532565A0 (fr)
FI (1) FI78479C (fr)
HK (1) HK91989A (fr)
HU (1) HU192404B (fr)
IE (1) IE57487B1 (fr)
IL (1) IL71863A (fr)
MX (1) MX9203001A (fr)
NO (1) NO163618C (fr)
NZ (1) NZ208188A (fr)
PH (1) PH20016A (fr)
PL (2) PL142760B1 (fr)
PT (1) PT78604B (fr)
RU (2) RU2071471C1 (fr)
SG (1) SG25086G (fr)
ZA (1) ZA843746B (fr)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5028610A (en) * 1987-03-18 1991-07-02 Sankyo Company Limited N-benzhydryl-substituted heterocyclic derivatives, their preparation and their use
DE68913965T2 (de) * 1988-12-26 1994-08-04 Kowa Co Herstellung von glycidyläther.
EP0714660B1 (fr) * 1989-06-23 2002-09-04 Syntex (U.S.A.) LLC Ranolazine et pipérazines apparentées pour la protection des muscles du squelette
HU209723B (en) * 1990-10-31 1994-10-28 Richter Gedeon Vegyeszet Process for producing of piperazine derivatives
US5455045A (en) * 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
WO1996040664A2 (fr) * 1995-06-07 1996-12-19 Dade Chemistry Systems Inc. Preparations d'immunogenes et d'autres conjugues de medicaments
US6303607B1 (en) * 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
US6479496B1 (en) * 1998-09-10 2002-11-12 Cv Therapeutics, Inc. Methods for treating angina with ranolazine
US6528511B2 (en) * 2000-02-18 2003-03-04 Cv Therapeutics, Inc. Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure
US6552023B2 (en) * 2000-02-22 2003-04-22 Cv Therapeutics, Inc. Aralkyl substituted piperazine compounds
US6677336B2 (en) * 2000-02-22 2004-01-13 Cv Therapeutics, Inc. Substituted piperazine compounds
US6638970B2 (en) 2000-02-22 2003-10-28 Cv Therapeutics, Inc. Substituted alkylene diamine compounds
WO2001062744A2 (fr) * 2000-02-22 2001-08-30 Cv Therapeutics, Inc. Composes de piperazine substitues
US6677343B2 (en) 2000-02-22 2004-01-13 Cv Therapeutics, Inc. Substituted piperazine compounds
US6451798B2 (en) * 2000-02-22 2002-09-17 Cv Therapeutics, Inc. Substituted alkyl piperazine derivatives
US20020052377A1 (en) * 2000-07-21 2002-05-02 Wolff Andrew A. Method for treating angina
US6693099B2 (en) * 2000-10-17 2004-02-17 The Procter & Gamble Company Substituted piperazine compounds optionally containing a quinolyl moiety for treating multidrug resistance
US6573264B1 (en) 2000-10-23 2003-06-03 Cv Therapeutics, Inc. Heteroaryl alkyl piperazine derivatives
US7001909B2 (en) * 2001-07-19 2006-02-21 Cv Therapeutics, Inc. Substituted heterocyclic compounds
NZ530705A (en) * 2001-07-19 2005-08-26 Cv Therapeutics Inc Substituted piperazine compounds and their use as fatty acid oxidation inhibitors
JP4625637B2 (ja) 2002-02-22 2011-02-02 シャイア エルエルシー 活性物質送達系及び活性物質を保護し投与する方法
US20030220344A1 (en) * 2002-04-04 2003-11-27 Luiz Belardinelli Method of treating arrhythmias
US20080109040A1 (en) * 2002-04-04 2008-05-08 Luiz Belardinelli Method of treating arrhythmias
CA2486712C (fr) * 2002-05-21 2012-01-03 Cv Therapeutics, Inc. Methode permettant de traiter le diabete
US8822473B2 (en) * 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
DE60327765D1 (de) 2002-06-24 2009-07-09 Janssen Pharmaceutica Nv Verfahren zur herstellung von n-(2,6-dimethylphenyl)-2-piperazin-1-ylacetamid
US7056924B2 (en) * 2002-07-18 2006-06-06 Cv Therapeutics, Inc. Substituted heterocyclic compounds
NZ540548A (en) * 2002-12-05 2008-03-28 Cv Therapeutics Inc Substituted piperazine compounds and their use as fatty acid oxidation inhibitors
EP1806346B1 (fr) * 2002-12-05 2009-07-22 Cv Therapeutics, Inc. Dérivés de Pipérazine substitués et leur utilisation comme inhibiteurs de l'oxydation d'acids gras
WO2004063180A1 (fr) * 2003-01-03 2004-07-29 Cv Therapeutics, Inc. Composes heterocycliques substitues
KR20050092424A (ko) * 2003-01-17 2005-09-21 씨브이 쎄러퓨틱스, 인코포레이티드 심혈관 질환의 치료에 유용한 치환된 헤테로고리 화합물
AU2004252102A1 (en) * 2003-06-23 2005-01-06 Gilead Palo Alto, Inc. Urea derivatives of piperazines and piperidines as fatty acid oxidation inhibitors
EP1723129A1 (fr) 2003-12-18 2006-11-22 Cv Therapeutics, Inc. Composes piperazine et piperazine 1-akan-2-ol substitues
WO2006008753A1 (fr) * 2004-07-19 2006-01-26 Unichem Laboratories Limited Forme cristalline et amorphe de ranolazine et son processus de fabrication
WO2006029179A2 (fr) * 2004-09-08 2006-03-16 Cv Therapeutics, Inc. Composes heterocycliques substitues
KR20070093988A (ko) * 2005-01-06 2007-09-19 씨브이 쎄러퓨틱스, 인코포레이티드 라놀라진 함유 서방성 약제학적 제형물
WO2008047388A2 (fr) * 2006-10-20 2008-04-24 Ind-Swift Laboratories Limited Procédé amélioré de préparation de ranolazine
US20090111826A1 (en) * 2007-02-13 2009-04-30 Louis Lange Use of ranolazine for the treatment of cardiovascular diseases
CA2677931A1 (fr) 2007-02-13 2008-08-21 Cv Therapeutics, Inc. Utilisation de la ranolazine pour le traitement de maladies cardiovasculaires
JP2010518171A (ja) * 2007-02-13 2010-05-27 ギリアード・パロ・アルト・インコーポレイテッド 非冠微小血管疾患の処置のためのラノラジンの使用
CA2678319A1 (fr) * 2007-02-13 2008-08-21 Cv Therapeutics, Inc. Utilisation de la ranolazine dans le traitement des maladies microvasculaires coronaires
ES2395241T3 (es) * 2007-03-07 2013-02-11 Concert Pharmaceuticals Inc. Derivados deuterados de piperazina como compuestos antianginosos
US20080233191A1 (en) * 2007-03-22 2008-09-25 Brent Blackburn Use of ranolazine for elevated brain-type natriuretic peptide
WO2008139492A2 (fr) * 2007-05-15 2008-11-20 Natco Pharma Limited Procédé de préparation de base de ranolazine de haute pureté
EA200971073A1 (ru) * 2007-05-31 2010-08-30 Джилид Пало Альто, Инк. Применение ранолазина при повышенном уровне натрийуретического пептида мозгового типа
JP2010529994A (ja) * 2007-06-13 2010-09-02 オースペックス・ファーマシューティカルズ・インコーポレイテッド 置換ピペラジン
US20090247535A1 (en) * 2008-03-26 2009-10-01 Duke University Use of ranolazine for non-cardiovascular disorders
AR072196A1 (es) * 2008-06-19 2010-08-11 Medichem Sa Procedimiento para preparar ranolazina purificada, util en el tratamiento cronico de la angina.
WO2010025370A2 (fr) * 2008-08-28 2010-03-04 Dr. Reddy's Laboratories Ltd. Préparation de ranolazine
WO2010023687A2 (fr) * 2008-08-28 2010-03-04 Shodhana Laboratories Limited Préparation de la ranolazine, ses sels et des intermédiaires de ceux-ci
US20110300218A1 (en) * 2008-09-09 2011-12-08 Actavis Group Ptc Ehf Novel solid state forms of ranolazine salts
US20110223213A1 (en) * 2008-10-15 2011-09-15 Actavis Group Ptc Ehf Highly pure ranolazine or a pharmaceutically acceptable salt thereof
WO2010097805A1 (fr) 2009-02-24 2010-09-02 Lupin Limited Procédé pour la préparation de ranolazine
US8901128B2 (en) 2009-05-28 2014-12-02 Lupin Limited Pharmaceutical compositions of ranolazine
WO2011036677A2 (fr) 2009-09-25 2011-03-31 Lupin Limited Composition de ranolazine à libération prolongée
TWI508726B (zh) 2009-12-21 2015-11-21 Gilead Sciences Inc 治療心房纖維性顫動之方法
TW201215392A (en) 2010-06-16 2012-04-16 Gilead Sciences Inc Use of ranolazine for treating pulmonary hypertension
NO3175985T3 (fr) 2011-07-01 2018-04-28
WO2013043925A1 (fr) 2011-09-21 2013-03-28 Gilead Sciences, Inc. Bloqueurs des canaux sodiques réduisant la sécrétion de glucagon
CN103570645A (zh) * 2012-08-01 2014-02-12 上海迪赛诺化学制药有限公司 一种制备n-(2,6-二甲基苯基)-2-(1-哌嗪基)乙酰胺的方法
US10266507B2 (en) 2015-03-10 2019-04-23 Unichem Laboratories Limited Process for the preparation of ranolazine
TW201717919A (zh) 2015-07-02 2017-06-01 國際藥品股份公司 雷諾多重壓縮錠劑
WO2018001582A1 (fr) 2016-06-30 2018-01-04 Interquim, S.A. Comprimés multiples à base de ranolazine

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3829441A (en) * 1962-01-29 1974-08-13 Smith Kline French Lab Guanidinoalkylbenzodioxan derivatives
US3360529A (en) * 1962-01-29 1967-12-26 Smith Kline French Lab Guanidinoalkylbenzodioxan derivatives
US3496183A (en) * 1964-11-19 1970-02-17 Egyt Gyogyszervegyeszeti Gyar Beta-guanidino-ethyl-piperazine derivatives
DE1795362A1 (de) * 1968-09-19 1972-01-05 Boehringer Mannheim Gmbh Basische AEther und Verfahren zur Herstellung derselben
DE1795375A1 (de) * 1968-09-21 1972-01-05 Boehringer Mannheim Gmbh Basische AEther und Verfahren zur Herstellung derselben
FR2154493B1 (fr) * 1971-09-13 1975-10-31 Kali Chemie Ag
GB1332008A (en) * 1971-09-28 1973-10-03 Pfizer Ltd Piperazine derivatives their preparation and pharmaceutical compositions containing them
GB1374366A (en) * 1972-07-21 1974-11-20 Science Union & Cie Propanol derivatives and a process for their preparation
GB1425559A (en) * 1972-09-01 1976-02-18 Wyeth John & Brother Ltd Pyridine tetrahydropyridine and piperidine derivatives
GB1411531A (en) * 1972-10-24 1975-10-29 Lafon Labor Amino derivatives of 1,4-benzodioxan
US3953448A (en) * 1972-12-07 1976-04-27 Delmar Chemicals Limited Piperazino-anilido compounds
FR2267104A1 (en) * 1974-04-12 1975-11-07 Ferlux Labo Sa Hypotensive and antiarrhythmic piperazines - 1-(3-phenoxy-2-hydroxy propyl)-4-substd. piperazines
FR2310763A1 (fr) * 1975-05-13 1976-12-10 Buzas Andre Derives 1,4-disubstitues de la piperazine, leur procede de preparation et leurs applications
US4335126A (en) * 1977-03-10 1982-06-15 Degussa Aktiengesellschaft 1-[3-(3,4,5-Trimethoxyphenoxy)-2-hydroxy-propyl]-4-aryl-piperazine-derivatives having pharmaceutical activity
FR2462432A2 (fr) * 1979-08-03 1981-02-13 Delalande Sa Nouveaux derives de la 3,4,5 trimethoxy cinnamoyle piperazine, leur procede de preparation et leur application en therapeutique
FR2387971A1 (fr) * 1977-04-19 1978-11-17 Delalande Sa Nouvelles trimethoxy cinnamoyles piperazines, leur procede de preparation et leur application en therapeutique
FR2456738A2 (fr) * 1978-04-10 1980-12-12 Delalande Sa Nouvelles cinnamoyles piperazines et homopiperazines, leur procede de preparation et leur application en therapeutique
JPS6042795B2 (ja) * 1978-10-23 1985-09-25 日本新薬株式会社 カルバモイルピペラジン誘導体
EP0025111B1 (fr) * 1979-08-10 1984-07-25 Sandoz Ag Dérivés 3-aminopropoxyaryliques, leur préparation et compositions pharmaceutiques les contenant
DE2941597A1 (de) * 1979-10-13 1981-04-23 Basf Ag, 6700 Ludwigshafen Piperidinderivate von 4,5-dialkyl-3-hydroxy-pyrrol-2-carbonsaeureestern, ihre herstellung und diese enthaltende pharmazeutische zubereitungen
US4368199A (en) * 1980-01-21 1983-01-11 Delalande S.A. Novel derivatives of 3,4,5-trimethoxy cinnamoyl piperazine, their salts, the process for preparing the same and their application in therapeutics
DE3005287A1 (de) * 1980-02-13 1981-08-20 Basf Ag, 6700 Ludwigshafen Phenylpiperazinderivate von 1,3,4-oxadiazolylphenolen, ihre herstellung und diese enthaltende therapeutische mittel
US4302469A (en) * 1980-09-10 1981-11-24 Syntex (U.S.A.) Inc. 2-(1,4-Benzodioxan-2-ylalkyl)imidazoles useful as antidepressants
US4684651A (en) * 1981-03-17 1987-08-04 Mitsubishi Chemical Industries Limited Alkylenedioxybenzene and acid addition salts thereof useful as hypotensives
US4766125A (en) * 1981-06-23 1988-08-23 Janssen Pharmaceutica N.V. N-aryl-piperazinealkanamides useful for protecting hearts from myocardial injury caused by ischaemia, anoxia or hypoxia
US4374837A (en) * 1981-07-31 1983-02-22 Laroche Navarron, S.A. Piperazine derivatives of theobromine
US4353901A (en) * 1981-10-19 1982-10-12 Syntex (U.S.A.) Inc. 9-(1,4-Benzodioxan-2-ylalkyl and hydroxyalkyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-ones

Also Published As

Publication number Publication date
US4567264A (en) 1986-01-28
ZA843746B (en) 1986-01-29
RU2083570C1 (ru) 1997-07-10
IL71863A0 (en) 1984-09-30
PT78604B (en) 1986-07-15
PH20016A (en) 1986-09-01
ES8601947A1 (es) 1985-12-01
HU192404B (en) 1987-06-29
PL247722A1 (en) 1985-08-13
SG25086G (en) 1989-12-29
JPS59219271A (ja) 1984-12-10
MX9203001A (es) 1992-07-01
FI841989A (fi) 1984-11-19
ES532565A0 (es) 1985-12-01
DK168535B1 (da) 1994-04-18
FI78479B (fi) 1989-04-28
KR890000020B1 (ko) 1989-03-06
JPH0469151B2 (fr) 1992-11-05
FI841989A0 (fi) 1984-05-17
ATE31533T1 (de) 1988-01-15
IE841224L (en) 1984-11-18
PL143558B1 (en) 1988-02-29
BR1100474A (pt) 2000-03-14
CS246080B2 (en) 1986-10-16
KR850002475A (ko) 1985-05-13
AU2834684A (en) 1984-11-22
HK91989A (en) 1989-11-24
RU2071471C1 (ru) 1997-01-10
PL142760B1 (en) 1987-11-30
DK248384A (da) 1984-11-19
HUT34177A (en) 1985-02-28
PT78604A (en) 1984-06-01
NO841968L (no) 1984-11-19
NZ208188A (en) 1987-10-30
DE3468215D1 (en) 1988-02-04
EP0126449A1 (fr) 1984-11-28
DK248384D0 (da) 1984-05-17
IE57487B1 (en) 1993-02-10
IL71863A (en) 1987-10-30
FI78479C (fi) 1989-08-10
PL252856A1 (en) 1985-11-19
EP0126449B1 (fr) 1987-12-23
NO163618B (no) 1990-03-19
AU566489B2 (en) 1987-10-22
CA1256874A (fr) 1989-07-04

Similar Documents

Publication Publication Date Title
NO163618C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive aryloksy- og aryltio-hydroksypropyl-piperazin-acetanilider.
FI893632A0 (fi) Foereningar.
NO159593C (no) Analogifremgangsm te for fremstilling av terapeutisk virksomme dihydropyridinderivater.
NO903851L (no) Fremgangsmaate for fremstilling av n-substituerte-4-pyrimidinaminer og -pyrimidindiaminer, og deres anvendelse som medikamenter.
KR950005817A (ko) 5원환을 갖는 벤조-융합된 헤테로사이클릭 화합물, 이의 제조방법, 약제로서의 이의 용도, 진단제로서의 이의 용도 및 이를 함유하는 약제
NO166126C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive kinolonkarboksylsyrederivater.
NO173139C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 2-aminopyrimidinonderivater
NO874834D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive tienopyridinoner.
NO163568C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive kinolonkarboksylsyrederivater.
NO157377C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive imidazodiazepiner.
NO833900L (no) Fremgangsmaate for fremstilling av terapeutisk aktive naftalenderivater
NO171366C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive n-(3-alkyloksy-4-piperidinyl)benzamider
DK248886D0 (da) Spiro-imidazolidin-forbindelser og farmaceutiske praeparater indeholdende disse
SE8105689L (sv) Terapeutiska medel
EP0302757A3 (fr) Agents de dépletion de la sérotine ayant une activité antiémétique
NO803862L (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive fenylaminoimidazolin-derivater
ES8104265A1 (es) Un procedimiento para la preparacion de nuevas bencenosulfi-namidas
EA199700299A1 (ru) Азольные соединения с противогрибковой (антимикозной) активностью, применяемые для лечения людей и в ветеринарии
NO170414C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 2-tienyloksyeddiksyrederivater

Legal Events

Date Code Title Description
MK1K Patent expired